Field & Main Bank decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,563 shares of the medical research company’s stock after selling 305 shares during the quarter. Field & Main Bank’s holdings in Amgen were worth $970,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Maverick Capital Ltd. purchased a new position in Amgen in the first quarter worth $27,000. Regency Capital Management Inc. DE purchased a new position in Amgen in the first quarter worth $27,000. KB Financial Partners LLC purchased a new position in Amgen in the first quarter worth $35,000. Itau Unibanco Holding S.A. purchased a new position in Amgen in the second quarter worth $39,000. Finally, Lumature Wealth Partners LLC boosted its position in Amgen by 82.3% in the second quarter. Lumature Wealth Partners LLC now owns 175 shares of the medical research company’s stock worth $43,000 after purchasing an additional 79 shares during the last quarter. Hedge funds and other institutional investors own 74.95% of the company’s stock.
AMGN has been the topic of several research analyst reports. Daiwa Capital Markets cut Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 price objective on the stock. in a research report on Thursday, September 23rd. Oppenheimer cut their price objective on Amgen from $277.00 to $272.00 and set an “outperform” rating on the stock in a research report on Monday, November 1st. Royal Bank of Canada dropped their price target on Amgen from $217.00 to $216.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 3rd. Morgan Stanley dropped their price target on Amgen from $251.00 to $235.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 12th. Finally, Mizuho dropped their price target on Amgen from $222.00 to $194.00 and set a “neutral” rating on the stock in a research report on Monday. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $235.50.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 2nd. The medical research company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.22 by $0.45. Amgen had a return on equity of 108.67% and a net margin of 21.77%. During the same quarter last year, the business posted $4.37 EPS. Analysts forecast that Amgen Inc. will post 16.83 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 8th. Investors of record on Tuesday, November 16th will be paid a dividend of $1.76 per share. The ex-dividend date is Monday, November 15th. This represents a $7.04 dividend on an annualized basis and a dividend yield of 3.45%. Amgen’s payout ratio is 72.50%.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
Recommended Story: What is an overbought condition?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.